MIM
SGP

MetLife Investment Management’s SpyGlass Pharma SGP Stock Holding History

MetLife Investment Management’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$156K Buy
+6,986
New +$152K ﹤0.01% 2546

Other funds holding SGP

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

MetLife Investment Management's SGP Position: Q2 2026 in Review

MetLife Investment Management opened a new position in SpyGlass Pharma (SGP) in Q2 2026: 6,986 shares worth $156K. The stake represents ﹤0.01% of the portfolio and ranks #2546 among its holdings.

43 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

  • MetLife Investment Management held 6,986 shares of SpyGlass Pharma worth $156K as of Q2 2026.
  • SpyGlass Pharma was a new MetLife Investment Management position in Q2 2026.
  • SpyGlass Pharma made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2546 holding.
  • 43 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.